The FDA's incentivization of novel drugs

By Dr Nicola Davies

As of September 14, 2018, the US Food and Drug Administration had approved the launch of 36 novel drugs, not including vaccines, blood products and biologics.1 With less than three months left in 2018, is there still chance to surpass last year’s 21-year high of 46 approvals?2 This is certainly the hope for those invested in addressing the many unmet needs of patients who require novel treatments for symptom relief, says Dr Nicola Davies in her exclusive article for The Pharma Letter.

The current landscape of novel drug approvals